Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $261.7 million.

  • Summit Therapeutics' Liabilities and Shareholders Equity fell 4795.11% to $261.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1475.86%. This contributed to the annual value of $435.6 million for FY2024, which is 11461.55% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Liabilities and Shareholders Equity is $261.7 million, which was down 4795.11% from $324.0 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $664.2 million for Q4 2022, and its period low was $95.7 million during Q2 2022.
  • In the last 5 years, Summit Therapeutics' Liabilities and Shareholders Equity had a median value of $218.5 million in 2023 and averaged $257.9 million.
  • As far as peak fluctuations go, Summit Therapeutics' Liabilities and Shareholders Equity surged by 48582.04% in 2022, and later plummeted by 6944.31% in 2023.
  • Over the past 5 years, Summit Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $113.4 million in 2021, then skyrocketed by 485.82% to $664.2 million in 2022, then plummeted by 69.44% to $202.9 million in 2023, then skyrocketed by 114.62% to $435.6 million in 2024, then tumbled by 39.91% to $261.7 million in 2025.
  • Its Liabilities and Shareholders Equity was $261.7 million in Q3 2025, compared to $324.0 million in Q2 2025 and $383.8 million in Q1 2025.